Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Extends Work With Celladon, BMS

by Rick Mullin
November 10, 2014 | A version of this story appeared in Volume 92, Issue 45

Lonza and Celladon, a biotechnology firm specializing in cardiovascular gene therapy, have entered an agreement that could elevate a multiyear clinical manufacturing contract for Celladon’s Mydicar enzyme replacement therapy, currently in Phase IIb development, to a full-scale commercial manufacturing contract. Under the new agreement, Lonza is designing a facility to be built adjacent to its mammalian cell biologics manufacturing operation in Portsmouth, N.H. If the project proceeds to commercial production, Lonza will purchase $10 million worth of Celladon common stock. Meanwhile, Lonza has expanded its biologics manufacturing agreement with Bristol-Myers Squibb. The contract expansion will include production of commercial quantities of a second BMS biologic medicine at Portsmouth.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.